These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21383771)
1. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Chan SL; Suo C; Lee SC; Goh BC; Chia KS; Teo YY Pharmacogenomics J; 2012 Aug; 12(4):312-8. PubMed ID: 21383771 [TBL] [Abstract][Full Text] [Related]
2. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192 [TBL] [Abstract][Full Text] [Related]
3. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676 [TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326 [TBL] [Abstract][Full Text] [Related]
5. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826 [TBL] [Abstract][Full Text] [Related]
6. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348 [TBL] [Abstract][Full Text] [Related]
7. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444 [TBL] [Abstract][Full Text] [Related]
8. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539 [TBL] [Abstract][Full Text] [Related]
9. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746 [TBL] [Abstract][Full Text] [Related]
10. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313 [TBL] [Abstract][Full Text] [Related]
11. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069 [TBL] [Abstract][Full Text] [Related]
12. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499 [TBL] [Abstract][Full Text] [Related]
13. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126 [TBL] [Abstract][Full Text] [Related]
14. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946 [TBL] [Abstract][Full Text] [Related]
15. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136 [TBL] [Abstract][Full Text] [Related]
17. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Zambon CF; Pengo V; Padrini R; Basso D; Schiavon S; Fogar P; Nisi A; Frigo AC; Moz S; Pelloso M; Plebani M Pharmacogenomics; 2011 Jan; 12(1):15-25. PubMed ID: 21174619 [TBL] [Abstract][Full Text] [Related]
18. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253 [TBL] [Abstract][Full Text] [Related]
19. The pharmacogenetics of the response to warfarin in Chinese. Lam MP; Cheung BM Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024 [TBL] [Abstract][Full Text] [Related]